BR0308415A - Methods of treating diabetes using pde11a inhibitors - Google Patents

Methods of treating diabetes using pde11a inhibitors

Info

Publication number
BR0308415A
BR0308415A BR0308415-9A BR0308415A BR0308415A BR 0308415 A BR0308415 A BR 0308415A BR 0308415 A BR0308415 A BR 0308415A BR 0308415 A BR0308415 A BR 0308415A
Authority
BR
Brazil
Prior art keywords
pde11a
inhibitors
methods
insulin
diabetes
Prior art date
Application number
BR0308415-9A
Other languages
Portuguese (pt)
Inventor
Haren Vasavada
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BR0308415A publication Critical patent/BR0308415A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"MéTODOS DE TRATAMENTO DE DIABETES USANDO-SE INIBIDORES DE PDE11A". A presente invenção refere-se a métodos de tratamento de diabetes, particularmente diabetes de tipo 2, e distúrbios relacionados por administração de um inibidor de PDE11A. Tais inibidores de PDE11A podem ser administrados em combinação com inibidores de alfa-glucosidase, sensibilizadores de insulina, secretagogos de insulina, compostos de diminuição de produção de glicose hepática, agonista beta3 ou insulina. Tais inibidores de PDE11A podem também ser administrados em combinação com agentes de redução de peso de corpo. Outros métodos da invenção referem-se a estimulação de liberação de insulina a partir de células pancreáticas, particularmente em resposta a uma elevação em concentração de glicose no sangue, por administração de um inibidor de PDE11A."DIABETES TREATMENT METHODS USING PDE11A INHIBITORS". The present invention relates to methods of treating diabetes, particularly type 2 diabetes, and related disorders by administration of a PDE11A inhibitor. Such PDE11A inhibitors may be administered in combination with alpha-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose-lowering compounds, beta3 agonist or insulin. Such PDE11A inhibitors may also be administered in combination with body weight reducing agents. Other methods of the invention relate to stimulation of insulin release from pancreatic cells, particularly in response to an elevation in blood glucose concentration, by administration of a PDE11A inhibitor.

BR0308415-9A 2002-03-14 2003-03-14 Methods of treating diabetes using pde11a inhibitors BR0308415A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36469702P 2002-03-14 2002-03-14
US38903602P 2002-06-13 2002-06-13
PCT/US2003/008132 WO2003077949A2 (en) 2002-03-14 2003-03-14 Methods of treating diabetes using pde 11a inhibitors

Publications (1)

Publication Number Publication Date
BR0308415A true BR0308415A (en) 2005-02-15

Family

ID=28045431

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308415-9A BR0308415A (en) 2002-03-14 2003-03-14 Methods of treating diabetes using pde11a inhibitors

Country Status (7)

Country Link
EP (1) EP1496940A2 (en)
JP (1) JP2005527524A (en)
AU (1) AU2003220342B2 (en)
BR (1) BR0308415A (en)
CA (1) CA2477832A1 (en)
MX (1) MXPA04008195A (en)
WO (1) WO2003077949A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005124359A2 (en) * 2004-06-15 2005-12-29 Metabolex, Inc. Methods of diagnosing and treating diabetes and insulin resistance
AU2007293885A1 (en) 2006-09-07 2008-03-13 Takeda Gmbh Combination treatment for diabetes mellitus
WO2008149345A2 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US20090239886A1 (en) 2008-02-29 2009-09-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8575217B2 (en) * 2009-03-16 2013-11-05 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
JP2015067538A (en) * 2013-09-26 2015-04-13 株式会社アイエイアイ Hypoglycemic agent
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU2001285782A1 (en) * 2000-06-26 2002-01-08 Bayer Aktiengesellschaft Regulation of human phosphodiesterase-like enzyme
EP1211313A3 (en) * 2000-11-01 2003-04-23 Pfizer Limited Modulation of PDE11A activity

Also Published As

Publication number Publication date
EP1496940A2 (en) 2005-01-19
WO2003077949A2 (en) 2003-09-25
JP2005527524A (en) 2005-09-15
WO2003077949A3 (en) 2004-03-25
AU2003220342A1 (en) 2003-09-29
CA2477832A1 (en) 2003-09-25
MXPA04008195A (en) 2004-11-26
AU2003220342B2 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
Szentesi et al. Changes in redox signaling in the skeletal muscle with aging
Werner et al. Erectile dysfunction in mice lacking the large‐conductance calcium‐activated potassium (BK) channel
BR112012018500A2 (en) some quinurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of use thereof
EA200900940A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PYRAZOL-O-GLUCOSIDE DERIVATIVE
BRPI0618918B8 (en) use of a first compound and a second compound to treat a blood glucose condition
BRPI0516825A (en) hepatitis c virus protease ns3-ns4a inhibition (vhc)
EA201101187A1 (en) ANTI-DIABETIC MEDICINES CONTAINING DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONAL IN COMBINATION WITH OTHER ANTI-DIABETIC MEANS
BRPI0408784A (en) method to use a compound
BRPI0507657A (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method for treating a disorder, and use of a compound or a pharmaceutically acceptable salt thereof
BRPI0416212A (en) pyridazinone derivative, pharmaceutical composition, use of the derivative, method for treating a subject afflicted with a condition or disease amenable to phosphodiesterase 4 inhibition and combination product
BRPI0512535A (en) unsubstituted piperidine compounds, their compositions and methods of modulation
EP1742643A4 (en) Modulation of glucose-6-phosphatase translocase expression
BRPI0415397A (en) methods and reagents for the treatment of immunoinflammatory disorders
DE69930739D1 (en) TRANSDERMALE USE OF SEKRETIN FOR THE TREATMENT OF AUTISM
JP2005521679A (en) Useful treatment for pain
DE602004030353D1 (en) FORMULATIONS CONTAINING SALICYLATES AND ITS USE IN THE TREATMENT OF INFLAMMATORY ENDURANCE
CR9078A (en) DERIVED FROM BENCIMIDAZOL ARILOXI-SUBSTITUTES
NO20043871L (en) Controlled release drug formulations containing a carrier peptide
EA200501710A1 (en) SUBSTITUTED CARBON ACIDS
CA2958696C (en) Formulations of testosterone and methods of treatment therewith
BR9917005A (en) Combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
EA200800397A1 (en) TIZANIDINE COMPOSITIONS AND TREATMENT METHODS USING COMPOSITIONS
BR0308415A (en) Methods of treating diabetes using pde11a inhibitors
DE60334147D1 (en) PLACENTAL ALKALINE PHOSPHATASE FOR DIABETES CONTROL
BR0012175A (en) Igiur5 receptor antagonists, selective for the treatment of migraine

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 3A, 4A, 5A, 6A E 7A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.